Clover Health Investments - Earnings Call - Q2 2025

Executive Summary

• Q2 2025 delivered strong top-line and membership growth with total revenues at $477.6M (+34% y/y) and MA membership at 106,323 (+32% y/y), while GAAP net loss from continuing operations was $10.6M and Insurance BER rose to 88.4% due to supplemental benefit and Part D utilization.
• Guidance was tightened: membership range raised to 104k–108k, Adjusted SG&A improved to $335M–$345M, and Insurance BER increased to 88.5%–89.5%; Adjusted EBITDA ($50M–$70M) and Adjusted Net Income ($50M–$70M) maintained.
• Management emphasized sustained adjusted profitability alongside >30% membership/revenue growth and highlighted 2026 tailwinds from moving to a four-star payment year and favorable CMS rate notice dynamics; 97% of members are in wide-network PPO plans.
• Key near-term watch items: continued variability from first-year IRA Part D changes, seasonal utilization in H2 (particularly Q4), and cohort mix effects from strong new-member growth; claims-payable days normalized to 32 days in Q2.
• Potential stock catalysts: raised membership guidance, operating leverage via SG&A improvement, visible tech-enabled care (COPD/CHF whitepapers), and 2026 four-star payment year positioning.

What Went Well and What Went Wrong

What Went Well

• Sustained growth and operating leverage: Revenues grew 34% y/y to $477.6M and Adjusted SG&A fell to 17.3% of revenues (down ~280 bps y/y), showing leverage despite growth-related variable costs.
• Membership and PPO positioning: MA membership reached 106,323 (+32% y/y), with 97% of members in wide-network PPO—management sees competitive advantage in PPO as peers pull back.
• Technology-led clinical impact: New COPD and earlier CHF analyses showed associations with fewer hospitalizations/readmissions and improved specialty access, reinforcing Clover Assistant/Counterpart value proposition.

What Went Wrong

• Insurance BER pressure: Insurance BER rose to 88.4% (vs. 76.1% in Q2 2024), with elevated supplemental (notably dental) and first-year IRA Part D utilization, prompting guidance increase to 88.5%–89.5%.
• Profitability mixed: GAAP net loss from continuing operations was $10.6M; Adjusted EBITDA and Adjusted Net Income declined y/y given utilization pockets (Q2 2025 Adjusted EBITDA $17.1M vs. $36.2M in Q2 2024).
• Modeling uncertainty: Management flagged Part D as a “known unknown” in H2 due to limited historical baseline and industry-wide subsidy adjustments, increasing variability risk into year-end.

Transcript

Operator (participant)

Ladies and gentlemen, good afternoon, and welcome to the Clover Health Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the prepared remarks. As a reminder, today's call is being recorded. I would now like to turn the call over to Ryan Schmidt, Investor Relations for Clover Health. Please go ahead.

Ryan Schmidt (IR & FP&A Manager)

Good afternoon, everyone. Joining me on our call today to discuss the company's second quarter twenty twenty five results are our Chief Officer and Peter Kuipers, the company's Chief Financial Officer. You can find today's press release and the accompanying supplemental slides as well as the company's most recent investor deck in the Investor Events and Presentations section of our website at investors.cloverhealth.com. This webcast is being recorded and a replay will be available in the Investor Relations section of the Clover Health website. I'd also like to caution you that we may make forward looking statements during today's call that are subject to risks and uncertainties, including expectations about future performance.

Factors that may cause actual results to differ materially from expectations are detailed in our SEC filings, including in the Risk Factors section of our most recent annual report on Form 10 ks and other SEC filings. Information about non GAAP financial measures referenced, including a reconciliation of those measures to GAAP measures, can be found in the earnings materials available on our website. With that, I'll now turn the call over to Andrew.

Andrew Toy (CEO & Director)

Thank you, Ryan. Welcome everyone to our second quarter earnings call. We are happy to report that we delivered yet another impactful quarter this year, building our momentum and demonstrating our ability to achieve meaningful growth alongside sustained adjusted EBITDA profitability in Medicare Advantage through the first half of the year. To start, I feel we are executing well against our strategy. We have always aimed to position Clover to win over the long term within Medicare Advantage and our arc has been simple.

First, achieve profitability, then return to growth while sustaining profitability and then leverage our differentiated model to accelerate growth and profitability together. We exceeded our adjusted EBITDA profitability target in 2024. Through the 2025, we are executing well and believe that we are proving that we can achieve sustained adjusted EBITDA profitability amid meaningful membership and revenue growth all during a 3.5 star payment year. And most importantly, we expect that our performance in 2025 will position us very well to accelerate both growth and profitability in 2026, which is a four star payment year and where we will continue to offer our flagship wide network PPO plan while others retreat from that offering. Our trajectory is clear.

We are confident in the path ahead and while not all market plan data is available yet, we have reason to believe this will be another strong membership growth season for us, potentially even stronger than this year. Also with next year being a four star payment year, we feel we should be able to strongly grow 2026 adjusted EBITDA as well. Next, let's discuss how our second quarter highlights our strategic arc and the significant value our technology first care model brings to our members. As I mentioned, we're continuing to deliver robust membership and revenue growth this year alongside sustained adjusted EBITDA profitability in our business. Since last quarter, our Medicare Advantage book has continued to increase membership and we are now projecting ending 2025 with even more members.

This is not just growth for growth sake. We're making a real difference by bringing earlier care management via Clover Assistant technology to more and more Medicare Advantage seniors. We're of course proud of our financial results so far this year and I believe we have truly differentiated ourselves through the unmatched value we bring to our members. We continue to lead with physician choice, affordability and high quality healthcare through our technology first care model and we are driving real life results. And this ultimately is driving our growth and we believe is why seniors are choosing Clover Medicare Advantage plans.

As another example of our models impact, earlier this month, we published a clinical white paper on chronic or COPD showing that a relationship with a Clover assistant provider was correlated with fifteen percent fewer hospitalizations and eighteen percent fewer readmissions. Our results are more than just numbers on a page. They're a testament to the momentum we're building and the effectiveness of Clover Assistant to make a real world impact in better managing chronic diseases. Next, I would like to discuss broader industry managed care trends, particularly in the context of the pressures others are noting in the Medicaid and ACA markets. It's crucial to note that at Clover, our business is Medicare Advantage.

We do not run standalone Medicaid plans nor do we participate on the ACA exchanges. We do serve dual eligible members, but these Medicare Advantage individuals are by definition seniors or are disabled, meaning that they are not impacted by dynamics like work requirements within the construct of Medicaid redeterminations. As such, we believe that our Medicare Advantage focus should help insulate us from these broader industry pressures. However, we are also seeing some of the elevated cost trends within our MA book that others in the industry have identified. That said, we are generally satisfied with the underlying trends we're observing in our portfolio.

I would note that we are keeping a particularly close watch on the impacts from the Part D IRA changes this year. Given that this is the first year of the new program, there is less of a historic baseline to trend against. And so we anticipate more variability in our modeling of performance. As such, we are diligently monitoring this to see how it plays out through the remainder of the year. Put another way, while I think we are appropriately focused on delivering our care management model, we also recognize that Part D remains a big known unknown for the second half of the year.

This is also consistent with the recently published Part D direct subsidy rate, which is materially higher for 2026 than for 2025, signaling higher costs than expected by the industry. The good news is that this also gives us reason to believe that Part D pressure in 2025 might be alleviated in 2026. With all that said, against this backdrop of general managed care headwinds, we continue to believe our technology centric care delivery model differentiates us. Remember that our approach to managing total cost of care is fundamentally different. It's anchored on identifying and managing diseases as early as possible via Clover Assistant and simultaneously delivering crucial support through our Clover Care Services offering when and where our members need it most.

This unique approach allows us the potential to truly bend the cost curve over time for our members and effectively manage trends amidst broader industry pressures. To that end, we're extremely excited about the new health tech ecosystem initiative unveiled last week by CMS and the White House that focuses on building a truly patient centric interoperable ecosystem. This initiative fostering a smarter, more secure and personalized healthcare experience through enhanced interoperability and real time information sharing resonates deeply with the foundational principles we champion at Clover since day one. Clover Assistant is already built upon the very interoperability framework and FHIR standards highlighted last week, both utilizing data to generate actionable insights and contributing those insights back into the networks. Ultimately, Clover Assistant and AI technologies all scale with data.

And we see this initiative as turbocharging data access, which will then bring a significant accelerant to our technology approach. Looking to 2026, we anticipate building on our successful 2025 strategy with an even sharper focus on profitable growth in our bids. Our commitment to expanding Clover Assistance reach, emphasizing retention in existing markets and balancing new and returning member cohorts remain central to accelerating our growth strategy. While the competitive MA landscape will undoubtedly evolve, we're confident in our pricing and positioning next year during a four star payment year as we've already proven we can deliver strong MA performance during a 3.5 star payment year in 2025. This step up in our stars rating provides us with an additional financial tailwind in 2026 and we believe that this will also position us to continue to strengthen our insurance product.

We're proud of the growth and momentum we've achieved in our results so far this year and look forward to our flywheel starting to spin much faster as we go into 2026. Now let's discuss our counterpart health progress and overall strategy. Since we announced last year that we made our same CA technology platform available to other risk bearing entities, we've seen broad interest and uptake. Our belief is that everything in healthcare ultimately revolves around the health outcomes and total cost of care of a patient. Involved in delivering these outcomes are a number of healthcare ecosystem players, primary care physicians, risk bearing ACOs, pharmacies, large hospitals and of course, health insurers, both regional and national.

Counterpart Assistance can benefit all these third parties and the interest we've received through the deals we've already announced shows the varied application potential of the tool, both by scaling CA within our own plan and outside of it. In particular, we are seeing a lot of resonance with plans that need assistance with star ratings and HEDIS quality scores as well as managing costs within their PPO wide networks. Based on this, we are very excited to have pipeline deals and deployments across the healthcare ecosystem. As a reminder, while we aren't able to announce every customer, we have announced several large health system deals and we're very pleased with our progress with payer partners. Our MA plan also recently announced a pilot to use CA with independent pharmacies, bringing our technology to yet another often overlooked site of care.

I'm excited about our progress and I believe we are well on our way to showing that counterpart assistance is capable of powering Medicare Advantage, not just in our own plan, but in any managed care setting nationwide and that it's ready for prime time scale. In summary, we are focused on achieving our goals this year and are strategically positioning the company for the future. We're growing significantly, operating profitably and differentiating ourselves through our technology first model. Simultaneously, we are setting the stage for an even more impactful 2026, which we believe will cement our position as a leader in Medicare Advantage. Now I'll hand it over to Peter for a more detailed financial update.

Peter Kuipers (CFO)

Thank you, Andrew. Before we get to the financials, I want to emphasize our strong position in today's managed care environment. We are demonstrating great Medicare Advantage execution leading with a wide network PPO plan that currently serves 97% of our members. We have achieved over 30% membership growth, which is well above the industry, all while maintaining profitability on a 3.5 star payment year. We have outlined our year over year profitability drivers on Page eight of the earnings deck posted to our IR website.

We are absorbing typical new member growth headwinds through the strong economics of our returning cohorts. And while our variable and growth SG and A cost is increasing due to this strong growth, coupled with our strategic investments into our model, this is effectively balanced by ongoing cost efficiencies in our business, a topic I'll elaborate on later. Now diving into the financials. Our results reflect continued growth and momentum in Medicare Advantage with sustained adjusted EBITDA profitability through the 2025. We've grown both membership and revenue by more than 30% year over year and at the same time, we improved GAAP net loss from continuing operations by $4,000,000 to $12,000,000 and maintained our year to date adjusted EBITDA and adjusted net income steady at $43,000,000 and $42,000,000 respectively.

Our results powered by our technology first model of care reinforce our confidence in achieving our updated full year 2025 guidance. We believe this also positions us well for accelerated growth and a meaningful increase in profitability in 2026, which is a four star payment year. Now let's move to a more detailed review of our second quarter financial performance, drivers and our updated full year 2025 guidance. Clover's core fundamentals are strong with well above market insurance revenue and membership growth. Second quarter twenty twenty five Medicare Advantage membership grew 32% year over year to above 106,000 members.

This growth fueled a 34% increase in insurance revenue to $470,000,000 in the second quarter and similarly 34 percent growth year to date to $927,000,000 as compared to the prior year period. And as our strategic growth flywheel continues to spin, we're generally satisfied with the underlying trends we're observing in our portfolio. While we are seeing some of the elevated Medicare Advantage cost trends that others in the industry have identified, we remain confident in our ability to manage our book. Both new and returning member core performance has been strong, which we attribute to our differentiated tech first model of care to manage Part C cost trends and identify diseases as early as possible. That said, during the second quarter, we observed some elevated pockets of utilization within supplemental benefits as well as elevated Part D utilization from IRA impacts.

While this did negatively impact our results, we have implemented different initiatives to monitor and manage these developments going forward. As such, we slightly increased our full year 2025 insurance BER guidance to reflect these developments, which I will discuss in more detail later. As it relates to the elevated utilization levels we're seeing within Part B and as Andrew mentioned, we're keeping a close eye on the impacts from the first year of the IRA changes and we will continue to diligently monitor any evolving trends that we're seeing here. Moving to SG and A. We continue to drive operating leverage and efficiencies in our business amidst our strong growth.

Adjusted SG and A as a percentage of total revenues improved to 17% this quarter, a two eighty basis point improvement year over year. This demonstrates our ability to gain operating leverage amidst increased variable and growth SG and A costs necessarily to support a strong new membership growth this year. More importantly, our result is net of our continued strategic investments focused on stars, quality initiatives, further improving our home care and Clover Assistant platform capabilities and further accelerating the reach of CA in our MA plan as well as in our counterpart health offering, all while leveraging technology and AI to gain further efficiencies in our SG and A. Our focus remains on disciplined, strategic investments to create lasting value for More importantly, we have sustained our adjusted EBITDA profitability profile in tandem with our strong growth through the first half of this year. GAAP net loss was $11,000,000 this quarter, bringing year to date GAAP net loss to $12,000,000 and this represents an improvement year to date of $4,000,000 compared to the same period last year.

During the second quarter, in tandem with our continued strong membership and revenue growth, we delivered $70,000,000 in adjusted EBITDA and $70,000,000 of adjusted net income. For the year to date period, adjusted EBITDA reached $43,000,000 and adjusted net income is $42,000,000 both remaining steady year over year amidst 32% membership growth. This underscores the strength of our differentiated growth model, sound insurance operations and solid cohort management. In addition, our performance this quarter resulted in an insurance BER of 88.4% compared to 76.1% in the 2024, bringing our year to date insurance BER to 87.3 and developing in line with our updated guidance for the full year of 2025. As you may recall, last year during the 2024, we experienced heightened private period development that skews the year over year comparisons.

The year over year increase in insurance BER also includes the continued impact of our CA enabled affiliate entity focused on improving care coordination and health outcomes for our New Jersey plan and members. We continue to push forward with this initiative to drive higher quality and better health outcomes for our members via better care coordination services, unified care management and a deeper focus on our partnerships with local physicians. Lastly, days in claims payable was thirty two days as of 06/30/2025, representing a decrease of five days sequentially. This represents continued normalization of our claims inventory from early last year when we experienced an increase in claims backlog as a result of the industry wide change healthcare incident that occurred simultaneously with our back office business processing as a service and the ecosystem transition. In an effort to normalize our claims inventory since last year, we have accelerated our timeliness of claims payments.

We believe that we have now adequately normalized our claims inventory and that our DCP is within expected go forward ranges. Moving on to the balance sheet. We ended the second quarter with cash, cash equivalents and investments totaling $389,000,000 on a consolidated basis with $146,000,000 at the unregulated subsidiary level. During the 2025, cash flow from operating activities was $5,000,000 favorably impacted by our results this quarter, bringing our year to date cash flow used in operating activities to $11,000,000 We expect that our cash balances will remain strong for the remainder of 2025, which will allow us to continue to operate from a position of strength as we invest in our growth model in 2026 and beyond. Finally, we have maintained our full year 2025 adjusted net income and adjusted EBITDA profitability guidance, underscoring our continued business execution, strong intra year membership growth and the power of a differentiated model of care.

And while our overall outlook remains consistent, we are providing the following guidance updates to reflect the latest developments in our business. We are increasing our Medicare Advantage membership guidance to now average between 104,108 members, reflecting 32% membership growth year over year at the midpoint and continued intra year growth this year. We are reconfirming our insurance revenue of between $1,800,000,000 and $1,875,000,000 reflecting year over year growth of 37% at the midpoint of the range. We are improving our adjusted SG and A guidance to be between three thirty five million dollars and $345,000,000 This represents adjusted SG and A as a percentage of total revenue of 18% to 19% and is an approximate 300 basis point decrease or improvement year over year at the midpoint of the range. This reflects our continued ability to gain operating leverage in our business as we grow.

For the full year 2025, we are maintaining adjusted net income guidance of between $50,000,000 and $70,000,000 Lastly, we're updating our insurance BR guidance to a range of 88.5 to 89.5%. This incorporates the underlying trends we've observed this quarter in Part D and supplemental benefits discussed earlier. And notably, the impact of our MA membership growth outperformance so far this year. While new members inherently bring near term cost pressure as we bring them into our care model, we view this incremental membership growth positively as it further strengthens our conviction for 2026 and beyond, where these new members will mature into returning members in the future. And lastly, we continue to expect typical revenue medical cost seasonality during the second half of the year with customary elevated utilization, particularly during the fourth quarter.

That said, this is simply normal Medicare Advantage seasonality. We remain confident in our unique care model and are focused on empowering PCPs with technology to identify and manage chronic diseases as early as possible to effectively manage costs amidst broader industry pressures. In summary, we're executing well on our strategy this year, achieving strong Medicare Advantage performance with above market growth and sustained adjusted EBITDA profitability year to date, which we believe firmly positions us for continued success in 2026 and beyond. We remain confident in our trajectory for the following reasons. First, as Andrew mentioned earlier, we're confident in the growth path ahead.

And while not all market plan data is available yet, we have reason to believe that this will be another strong membership growth season for us. Our underlying financial performance allows us to continue to invest in quality and affordability for our members, fueling our growth flywheel as well as continued investments to expand the reach of Clover system to better manage new and returning member cohorts. Second, we're continuing to prioritize returning member retention in our 2026 bid strategy. We expect the unit economics of our large cohort of new members added in 2025 to significantly improve into 2026 as returning members. And we also expect a continued favorable impact from further improvement in our year three plus returning member cohorts.

Third, in 2026, we will increase to a four star payment year for our PPO plans, which brings financial tailwinds that will favorably impact our results as 97% of our members are currently enrolled in a wide network PPO plans. Fourth, we expect a compounding favorable impact from the CMS final rate notice announced earlier this year that affects the broader industry. Although this is particularly additive to Clover, given that we're moving from a 3.5 star payment year in 2025 to a four star rating for payment year 2026. Lastly, we believe that there will be an incremental impact from our efforts to gain operating leverage, via our initiatives to optimize variable fixed and growth SG and A costs. By leveraging this year's momentum and targeted investments in our care platform, we believe that we are strategically positioned to meaningfully increase profitability, drive strong growth and truly unlock Clover Health's full potential in 2026 and beyond.

Now I'll turn the call back to Andrew for closing comments.

Andrew Toy (CEO & Director)

Thanks, Peter. In conclusion, we have delivered significant adjusted EBITDA profitability, clearly executing our strategy. Our differentiated tech first care model is consistently delivering results to effectively manage costs and drive our strong performance. We remain confident in our full year 2025 performance and we believe we are strategically positioned for accelerated growth and sustained profitability unlocking Clover's full potential in the future. With that, let's open it up for questions.

Operator (participant)

Thank you. We will now be taking questions from Clover's research We will now take our first question from Jonathan Young with UBS.

Jonathan Yong (Equity Analyst)

I for taking the question guess to start, the MCR BER came in above kind of expectations here. I know you called out sub and Part D, but within the context of your raised guidance on the BER, how much conservatism do you kind of have embedded in there? And how much visibility do you have into how that trend will develop in the back half of the year?

Peter Kuipers (CFO)

Yes. Thanks, Jonathan, for the question. So the increase in the DER guide for the full year is mostly related to Part D and supplemental, mostly actually dental. So that's a positive for the members. We have initiatives in place to monitor this go forward.

And then we believe there's some relief as well on the Part D pressure from the IRA as we go into 2026.

Jonathan Yong (Equity Analyst)

Okay. And then within the context of what you saw, when did this pressures kind of start emerging? Was it in the earlier part of the quarter, later part of the quarter? And then how much of this did you actually capture within the context of your bids for next year, just given it does seem like a fairly sizable step up here?

Andrew Toy (CEO & Director)

Yes. I think that as I mentioned in my commentary, this is Andrew, the part especially on the Part D side, one thing we've been tracking as we go through the year is that this is the first year of the IRA. So tracking against the model is something new across the industry, I think. So we did look at that, excuse me, when we were pricing into the bid. I think you can see that I think a lot of people in the industry did that as well as reflected by the fact of the variability and increase in the Part D direct subsidy that came in for 2026.

So I do think that across the industry that higher Part D costs are being factored in as we start to look and rationalize that trend from earlier this year into our sort of like baseline models.

Operator (participant)

We'll go next to Matt Hewitt with Craig Hallum Capital Group.

Matthew Hewitt (Senior Research Analyst)

Good afternoon. Thanks for taking the questions. Maybe first up, you've increased or showing improvement in your SG and A or adjusted SG and A. I'm just curious, what are the drivers for those improvements? Are you kind of holding back on some of the hiring?

Or are you finding some new efficiencies within the model? Any color there would be helpful.

Peter Kuipers (CFO)

Yes, Matt. Thanks for the question. Yes, so mostly cost efficiencies. We started a company wide cost initiative to really rationalize the prices volume terms we get with most of our partnership contracts. Now that we are growing well above the industry and we're estimating that same growth also to remain for the next couple of years.

So we're very we are a very attractive partner. So a lot of that also comes from term renegotiations with partners.

Matthew Hewitt (Senior Research Analyst)

Got it. And then maybe kind of a separate question here. But in what kind of response have you been getting from the COPD white paper? Is that something that you can replicate? Are there other similar types of papers that you can publish that kind of highlight the benefits of using CA and kind of driving incremental business?

Andrew Toy (CEO & Director)

Yes, definitely. We're very proud of the papers that we're putting out. We obviously, COPD just came out. We had CHF come out maybe about a month I think or two ago, our flagship paper on CKD came out I think last year or the year before. We plan to keep producing this material and we think that our clover system use is definitely in our data shown to be as we can see in the white paper is correlated with better earlier diagnosis, management, care, total cost of care.

You can see that our scores, which remain one of the top in the country, there's a lot of these data points, which we're very, very proud of. It also flows into how we're talking about the offering in the counterpart context as well, where we point these results that are being driven by our technology with our own plan and it's something that we can bring to other plans in other markets.

Matthew Hewitt (Senior Research Analyst)

Excellent. Thank you.

Peter Kuipers (CFO)

Yes, of course.

Operator (participant)

We'll go next to John Penny with Canaccord Genuity.

John Pinney (VP - Equity Research)

John Penny on for Richard Close. Thanks for the questions. So going back to the BERs, the elevated cost trend you're seeing like kind of more localized in that like kind of newer cohort? Or is it pretty broad based? Is there any differences in geography there? Is it again pretty broad based?

Peter Kuipers (CFO)

Yes. This is Peter. I'll answer that question. So the cohorts are I want make sure that that message is clear at Lance. The cohorts in our unique model, TechFirst model, are performing as expected in line.

So for Part D and as a supplemental, we don't see a specific split or between new and returning members. So returning members are definitely improving from an MCR BER perspective as expected.

Andrew Toy (CEO & Director)

And I would also add in there that as we said in our previous commentary, as we model out parts, especially the Part D side of things, was in my section, this is the first year. We are still figuring out what the baseline models look like. The direct subsidy will increase going to 26. So as Peter mentioned, like I think there's reason to believe that any pressures we see there will be appropriately priced in industry wide going into next year as well. And we are also making sure that we keep an eye on supplemental benefits throughout the year.

John Pinney (VP - Equity Research)

Okay, great. Thanks. And then also just to touch on like the competitive landscape in the upcoming AEP. Is there anything like different that you'd call out on how your competitors are approaching this year going into 2026? Are they maybe pulling back a little bit less than they did last year?

Or anything you would call out on any differences in the competitive landscape compared to last year?

Andrew Toy (CEO & Director)

Yes, for sure. I think that obviously we're noting that cost trends like within managed care in general within even Medicare Advantage has been a lot of motion this year by the national players. The way that we see it is that the products that they're most pulling back, while all of them pretty much are pulling back to some extent, where they're pulling back counts and where they're pulling back is generally within that PPO wider network where they struggle to deploy their existing managed care capabilities. And I think that's an area where we are very strong based upon our technology from the counterpart side. So we feel good in our core markets.

We feel that if people are pulling back, they're quite likely to pull back back within those same markets because those are challenging for the same reasons that they're good for us. So that's why within our commentary, we said that while we don't have all the data yet, we feel like we're likely to be very well placed into this coming growth season.

Peter Kuipers (CFO)

And I would add to that as well to point out again, year 2026 is a four star payment year. So that's also a financial headwind allowing us to grow.

John Pinney (VP - Equity Research)

All right. Great. Thank you.

Operator (participant)

And that will conclude the Q and A portion of today's conference. I would now like to turn the call back over to Andrew Toy for any additional or closing remarks.

Andrew Toy (CEO & Director)

Fantastic. I want to thank everybody for joining us today. Thank you for taking the time and for your questions. Truly value everyone's interest in Clover Health and we'll be speaking with everyone again soon. Thanks again and enjoy the rest of your evening.

Operator (participant)

Thank you. This concludes today's Clover Health second quarter twenty twenty five earnings call and webcast. You may disconnect your line at this time. Have a wonderful day.